Aeglea BioTherapeutics Stock Forecast, Price & News

Aeglea BioTherapeutics (NASDAQ:AGLE) Frequently Asked Questions

Is Aeglea BioTherapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aeglea BioTherapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Aeglea BioTherapeutics stock.
View analyst ratings for Aeglea BioTherapeutics or view top-rated stocks.

How has Aeglea BioTherapeutics' stock price been impacted by Coronavirus (COVID-19)?

Aeglea BioTherapeutics' stock was trading at $5.38 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AGLE shares have decreased by 24.3% and is now trading at $4.07.
View which stocks have been most impacted by COVID-19.

Are investors shorting Aeglea BioTherapeutics?

Aeglea BioTherapeutics saw a increase in short interest in December. As of December 15th, there was short interest totaling 937,400 shares, an increase of 36.5% from the November 30th total of 686,500 shares. Based on an average daily trading volume, of 278,400 shares, the short-interest ratio is currently 3.4 days. Approximately 2.3% of the company's stock are sold short.
View Aeglea BioTherapeutics' Short Interest.

When is Aeglea BioTherapeutics' next earnings date?

Aeglea BioTherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 17th 2022.
View our earnings forecast for Aeglea BioTherapeutics.

How were Aeglea BioTherapeutics' earnings last quarter?

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE) released its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by $0.03. The biotechnology company earned $1.40 million during the quarter, compared to the consensus estimate of $1.38 million.
View Aeglea BioTherapeutics' earnings history.

What price target have analysts set for AGLE?

4 brokers have issued twelve-month target prices for Aeglea BioTherapeutics' shares. Their forecasts range from $9.00 to $20.00. On average, they expect Aeglea BioTherapeutics' stock price to reach $13.67 in the next twelve months. This suggests a possible upside of 235.8% from the stock's current price.
View analysts' price targets for Aeglea BioTherapeutics or view top-rated stocks among Wall Street analysts.

Who are Aeglea BioTherapeutics' key executives?

Aeglea BioTherapeutics' management team includes the following people:

• Anthony G. Quinn, President, Chief Executive Officer & Director
• Leslie Sloan, Chief Operating Officer
• Jonathan D. Alspaugh, Chief Financial Officer (LinkedIn Profile)
• Steven Weber, Chief Accounting Officer, VP & Controller
• Scott W. Rowlinson, Vice President-Research

What is Anthony Quinn's approval rating as Aeglea BioTherapeutics' CEO?

3 employees have rated Aeglea BioTherapeutics CEO Anthony Quinn on Glassdoor.com. Anthony Quinn has an approval rating of 100% among Aeglea BioTherapeutics' employees. This puts Anthony Quinn in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Aeglea BioTherapeutics' key competitors?

Some companies that are related to Aeglea BioTherapeutics include uniQure (QURE), Phibro Animal Health (PAHC), Atai Life Sciences (ATAI), Syndax Pharmaceuticals (SNDX), Ventyx Biosciences (VTYX), Kiniksa Pharmaceuticals (KNSA), Endo International (ENDP), PMV Pharmaceuticals (PMVP), Arcutis Biotherapeutics (ARQT), MacroGenics (MGNX), Edgewise Therapeutics (EWTX), Amryt Pharma (AMYT), Gossamer Bio (GOSS), Tango Therapeutics (TNGX) and Seres Therapeutics (MCRB).
View all of AGLE's competitors.

What other stocks do shareholders of Aeglea BioTherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aeglea BioTherapeutics investors own include Amarin (AMRN), ACADIA Pharmaceuticals (ACAD), Aldeyra Therapeutics (ALDX), Dynavax Technologies (DVAX), Kura Oncology (KURA), Aduro Biotech (ADRO), Axsome Therapeutics (AXSM), BioCryst Pharmaceuticals (BCRX), Celldex Therapeutics (CLDX) and Dicerna Pharmaceuticals (DRNA).

When did Aeglea BioTherapeutics IPO?

(AGLE) raised $60 million in an IPO on Thursday, April 7th 2016. The company issued 3,500,000 shares at a price of $16.00-$18.00 per share. UBS Investment Bank, BMO Capital Markets and Wells Fargo Securities acted as the underwriters for the IPO and Needham & Company was co-manager.

What is Aeglea BioTherapeutics' stock symbol?

Aeglea BioTherapeutics trades on the NASDAQ under the ticker symbol "AGLE."

Who are Aeglea BioTherapeutics' major shareholders?

Aeglea BioTherapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Pinnacle Wealth Planning Services Inc. (0.02%). Company insiders that own Aeglea BioTherapeutics stock include Anthony G Quinn, Armen Shanafelt and Jonathan Alspaugh.
View institutional ownership trends for Aeglea BioTherapeutics.

Which institutional investors are buying Aeglea BioTherapeutics stock?

AGLE stock was bought by a variety of institutional investors in the last quarter, including Pinnacle Wealth Planning Services Inc.. Company insiders that have bought Aeglea BioTherapeutics stock in the last two years include Anthony G Quinn, Armen Shanafelt, and Jonathan Alspaugh.
View insider buying and selling activity for Aeglea BioTherapeutics or or view top insider-buying stocks.

How do I buy shares of Aeglea BioTherapeutics?

Shares of AGLE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Aeglea BioTherapeutics' stock price today?

One share of AGLE stock can currently be purchased for approximately $4.07.

How much money does Aeglea BioTherapeutics make?

Aeglea BioTherapeutics has a market capitalization of $200.73 million. The biotechnology company earns $-80.89 million in net income (profit) each year or ($1.03) on an earnings per share basis.

How many employees does Aeglea BioTherapeutics have?

Aeglea BioTherapeutics employs 90 workers across the globe.

What is Aeglea BioTherapeutics' official website?

The official website for Aeglea BioTherapeutics is www.aegleabio.com.

Where are Aeglea BioTherapeutics' headquarters?

Aeglea BioTherapeutics is headquartered at 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746.

How can I contact Aeglea BioTherapeutics?

Aeglea BioTherapeutics' mailing address is 805 LAS CIMAS PARKWAY SUITE 100, AUSTIN TX, 78746. The biotechnology company can be reached via phone at (512) 942-2935, via email at [email protected], or via fax at 512-872-5121.